"Compared with CHOP -- cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), and prednisone -- plus rituximab, the combination of bendamustine and rituximab showed substantially lower toxicity and better complete response rates in a randomized Phase III trial, reported Mathias Rummel, MD, PhD, of University Hospital in Giessen, Germany."